These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 24268686)

  • 1. Natural ligands and antibody-based fusion proteins: harnessing the immune system against cancer.
    Vyas M; Koehl U; Hallek M; von Strandmann EP
    Trends Mol Med; 2014 Feb; 20(2):72-82. PubMed ID: 24268686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas.
    Hagelstein I; Lutz MS; Schmidt M; Heitmann JS; Malenke E; Zhou Y; Clar KL; Kopp HG; Jung G; Salih HR; Märklin M; Hinterleitner C
    Front Immunol; 2021; 12():653081. PubMed ID: 33936075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate.
    Chávez-Blanco A; De la Cruz-Hernández E; Domínguez GI; Rodríguez-Cortez O; Alatorre B; Pérez-Cárdenas E; Chacón-Salinas R; Trejo-Becerril C; Taja-Chayeb L; Trujillo JE; Contreras-Paredes A; Dueñas-González A
    Int J Oncol; 2011 Dec; 39(6):1491-9. PubMed ID: 21805029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NKG2D and its ligands.
    Obeidy P; Sharland AF
    Int J Biochem Cell Biol; 2009 Dec; 41(12):2364-7. PubMed ID: 19631280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of NKG2D ligands and increased sensitivity of tumor cells to NK cell-mediated cytotoxicity by hematoporphyrin-based photodynamic therapy.
    Park MJ; Bae JH; Chung JS; Kim SH; Kang CD
    Immunol Invest; 2011; 40(4):367-82. PubMed ID: 21314289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide.
    Kim JY; Bae JH; Lee SH; Lee EY; Chung BS; Kim SH; Kang CD
    J Immunother; 2008 Jun; 31(5):475-86. PubMed ID: 18463537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innate immune recognition and suppression of tumors.
    Hayakawa Y; Smyth MJ
    Adv Cancer Res; 2006; 95():293-322. PubMed ID: 16860661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NKG2D ligands: key targets of the immune response.
    González S; López-Soto A; Suarez-Alvarez B; López-Vázquez A; López-Larrea C
    Trends Immunol; 2008 Aug; 29(8):397-403. PubMed ID: 18602338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
    Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
    Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
    Zhang T; Barber A; Sentman CL
    Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma.
    Jachimowicz RD; Fracasso G; Yazaki PJ; Power BE; Borchmann P; Engert A; Hansen HP; Reiners KS; Marie M; von Strandmann EP; Rothe A
    Mol Cancer Ther; 2011 Jun; 10(6):1036-45. PubMed ID: 21525185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro IL-2 or IFN-α-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients.
    Konjević G; Mirjačić Martinović K; Vuletić A; Babović N
    Melanoma Res; 2010 Dec; 20(6):459-67. PubMed ID: 20938360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expressions of natural cytotoxicity receptors and NKG2D on decidual natural killer cells in patients having spontaneous abortions.
    Zhang Y; Zhao A; Wang X; Shi G; Jin H; Lin Q
    Fertil Steril; 2008 Nov; 90(5):1931-7. PubMed ID: 18023431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression of NKG2D ligands in multidrug-resistant nasopharyngeal carcinoma cell line CNE2/DDP and their effects on cytotoxicity of natural killer cells].
    Mei JZ; Guo KY; Wei HM; Song CY
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jun; 27(6):887-9. PubMed ID: 17584663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of CD24(+) ovarian cancer cells to anti-cancer drugs and natural killer cells.
    Koh J; Lee SB; Park H; Lee HJ; Cho NH; Kim J
    Biochem Biophys Res Commun; 2012 Oct; 427(2):373-8. PubMed ID: 22995296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
    Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
    FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation.
    Vacca P; Martini S; Garelli V; Passalacqua G; Moretta L; Mingari MC
    Eur J Immunol; 2013 Feb; 43(2):550-61. PubMed ID: 23192659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
    Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
    Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity.
    Kellner C; Hallack D; Glorius P; Staudinger M; Mohseni Nodehi S; de Weers M; van de Winkel JG; Parren PW; Stauch M; Valerius T; Repp R; Humpe A; Gramatzki M; Peipp M
    Leukemia; 2012 Apr; 26(4):830-4. PubMed ID: 22005785
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.